



LEADING MEDICINE: A TOWN HALL CONVERSATION WITH DR. MARC BOOM

Town Hall Conversation XXIX



Taking Stroke Care to the Next Level:

Patient-Centered Neurological Care

Today's Agenda


Discuss current challenges in stroke care
How should we meet this challenge?
How has virtual care changed our field?

The Baseline
State:

A 58-year-old woman comes
to the ER with dizziness and
blurry vision.

Stroke Triage in 2022





The Problem

Very human dependent

- How experienced and effective is the triage nurse?
- How busy are the providers?
- How experienced and effective is the radiologist?

Very environment dependent

- How crowded is the ER?
- How good are the resources at the facility?

Very patient dependent

- Risk factors?
- Able to tell their story?
- Did they come too late?

The Solution

Provide the highest-
level expertise first



Triage

- ER provider: ***go or no-go stroke call***
 - ***Tendency to over-call ~30% of cases “just in case”***
 - ***Unfortunately misses ~20% of subtle cases***
 - ***Meaning Roughly half of all calls are wrong***
- Stroke team evaluation



But
resources
are limited
so we need...

An infinitely intelligent,
Inexpensive,
Never tired,
Always ready assistant who is a
Good listener
And even better observer.

We need a...





Stroke
“Alexa”



Stroke App

Development of a Stroke App

- Always available, personal digital assistant who can answer one question:



Development of a Stroke App

- Always available, personal digital assistant who can answer one question:

**Is this
patient
having a
stroke?**

Development of a Stroke App

Data Rich Inputs:

Face

Speech


Imaging

Output:


Is this patient having a stroke?

SORT Study


- Used an iPhone X
 - Records patient facial movements describing a picture
 - Voice during spontaneous speech and after a prompt
- Only additional inputs are the ABCs:
 - Age, blood pressure, “chief complaint”
- Total time for interaction less than 5 mins and designed to seamlessly integrate into EMS or RN initial triage




Arm test



Development of a Stroke App



Tell me what is going on?




Eye tracking

“Look to the left then to the right”



58-year-old
woman with
dizziness and
blurry vision




Without glasses




With glasses

58-year-old
woman with
dizziness and
blurry vision



“Show me your
teeth”





Calculate “micro-expressions”


The image shows a close-up of a person's mouth. A green line traces the outline of the lips and teeth. Two horizontal red lines are drawn across the mouth, one above the upper teeth and one below the lower teeth. A vertical red line is drawn on the right side of the mouth, intersecting the horizontal lines. The word 'Height' is written in white text to the right of the vertical line, and the word 'Width' is written in white text below the lower horizontal line. A semi-transparent white circle is overlaid on the left side of the image, containing text and a small diagram of a rectangle with a vertical line and a horizontal line.

- **Ratio = Height / Width**

If the ratio is greater than 0.20, we think the patient's mouth is open wide enough.

Height

Width



Measure the contour of mouth, which is more accurate.

Opening Ratio = 0.27

Teeth Area Percentage(White/black) = 56%



Why us?

The key ingredient in the process is the connection we have to patients.

This allows us to create a high-quality data library.

Our current library has over 6 years of high-quality stroke patient data, over 300 videos of acute stroke patients, over 700 normal subjects, and more than 7000 acute stroke brain scans.

Google or Amazon cannot easily access patient data or front-line triage video/audio of actual patients to learn from, but we can use their tools with our library of normal/abnormal to create this tool.


Why now?

COVID has fundamentally changed the doctor-patient relationship.

Patients want to avoid unnecessary ER evaluations, but they do not want to delay treatment when it is critical.

We need tools like a Stroke App for wherever a patient needs care.

The pipeline from pilot trial to pivotal study




Tool Development

Our pilot study of 94 patients, using facial recognition alone versus the ER doctor.

Machine gets: ~30s video only

ER MD gets: patient, family, **CT scan**, labs, vitals, chart full of information, med school, residency, experience, etc., etc.

How close do you think our process came to detecting stroke?




Tool Performance

Our First Prototype of Stroke App with video only proved:

93%

sensitive for detection of stroke



“Hot off the press”

Our First Prototype of Stroke App with video only proved equal in all patients:

93%


Toward Rapid Stroke Diagnosis with Multimodal Deep Learning

Mingli Yu¹, Tongan Cai^{1*}, Xiaolei Huang¹, Kelvin Wong²,
John Volpi³, James Z. Wang¹, Stephen T.C. Wong²

¹ The Pennsylvania State University, University Park, USA


² TT and WF Chao Center for BRAIN & Houston Methodist Cancer Center,
Houston Methodist Hospital, Houston, Texas, USA

³ Eddy Scurlock Comprehensive Stroke Center, Department of Neurology, Houston
Methodist Hospital, Houston, Texas, USA



A 58-year-old woman comes to the ER with dizziness and blurry vision.

The Future State:



Summary

Our group has accomplished:

- Best in class CT processing that achieves “MRI like” stroke detection to replace the “stroke clock”
- A library of over 300 acute stroke patient videos
- A successful pilot study of facial recognition for stroke detection with high fidelity
- Presentations and publications of our data in national and international forums

A model for integrating augmented intelligence into a typical stroke workflow

Future work

A bright future for *augmented intelligence* in healthcare and at Houston Methodist as a Center of Excellence:

- World class data science and imaging expertise
- Diverse patients
- 20+ years of leadership in stroke trials
- Extensive and detailed database
- Integrity in data stewardship
- Active clinicians at the largest stroke center in the region

A *platform technology* with applications in Parkinson's, Alzheimer's, depression, epilepsy, and many more.

Future work

Delivering rapid, unparalleled expertise to the patient, regardless of distance or time.

Integrate with telestroke and advances in virtual care.

Acute TeleStroke


Rajan Gadhia, MD

October 21, 2022

- Stroke is the fifth leading cause of death in the United States. More than 140,000 people die each year from stroke in the United States.
- Stroke is the leading cause of serious, long-term disability in the United States.
- About 795,000 people have a stroke in the United States each year.
- Strokes can and do occur at ANY age. Nearly one fourth of strokes occur in people under the age of 65.


- In the United States, majority (~87%) of strokes occur in the setting of lack of blood flow to a part of the brain.
- Etiologies of which vary, but could be thrombotic, embolic, hemodynamic, or a combination.
- HTN remains the leading modifiable risk factor for stroke.
- Encompasses acute ischemic infarcts as well as transient ischemic attacks.

Ischemic Stroke



- 58-year-old woman (Jane Doe) brought to ED after being found altered and unsteady in a parking lot.


Geographical Disparities in Care



Timeline of Acute Stroke Therapy Trials

September 2008

ACUTE STROKE WORK FLOW



from LKN


thrombectomy with IV tPA vs. tPA alone

January 2015– MR CLEAN study shows added benefit of Endovascular thrombectomy within 6 hours of LKN

2015/2016– ES and EXTEND-IA, SWPRVASCAT study added benefit of Endovascular thrombectomy within 6 hours of LKN

HOUSTON Methodist

Houston Methodist Hospital Acute Stroke Work Flow Attachment A




Modified Rankin Scale (MRS)

- 0 No symptoms
- 1 No significant disability, despite symptoms; able to perform all usual duties and activities
- 2 Slight disability; unable to perform all previous activities but able to look after own affairs without assistance
- 3 Moderate disability; requires some help, but able to walk without assistance
- 4 Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance
- 5 Severe disability; bedridden, incontinent, and requires constant nursing care and attention
- 6 Death


Timeline of Acute Stroke Therapy Trials

May 2018 –



September 2008




January 2015–




November 2017–



December 1995 –




2015/2016–






January 2018–



May 2019 –




Evolution of Systems of Stroke Care



TeleStroke Implementation

*All PerfectServe communication to include the requesting ED MD/ IP MD / ED NP/ IP NP

TeleStroke Process Diagram: ED & IP



Technology and...



TeleStroke Video Evaluation



Tele-Neurology

Go-Live Timeline, Consults & Coverage

Tele-Neurology: Go-Live Timeline

6/26/2017



CSC: Houston
Methodist
The Woodlands

11/27/2017



PSC: Houston
Methodist
Willowbrook

9/17/2018



PSC: Houston
Methodist
West Houston

10/3/2019



PSC: Houston
Methodist
Sugar Land

3/10/2020



PSC: Houston
Methodist
Baytown

3/16/2020



PSC: Houston
Methodist
Clear Lake

6 ECC Locations: Sienna, Cinco Ranch, Cypress, Spring, The Woodlands, Deer Park (Added Dec 2020)

Tele-Neurology: Consults & Coverage

Tele-Stroke Consults & Patients

6,557 Consultations

June 2017 – YTD

3,815 Consultations

Jan 2021 – YTD

423 Patients

Transferred to a Comprehensive Stroke
Center

June 2017 – YTD



Rajan Gadhia, MD

Tele-Stroke Coverage

7 Board Certified Physicians

Monday – Friday:

7am – 4pm (daytime)

4pm to 7 am (after hours)

Saturday, Sunday, & HM Holidays:

24 hour coverage


Acute and Tele-Neurology

Go-Live & Growth Timelines

Tele-Neurology: Go-Live Timeline



Tele-Neurology: Growth Timeline



TeleStroke during COVID-19

Publication: Door to Needle (DTN)



International Journal of
Neurological Disorders

Brief Report

COVID-Care: Rapid Expansion of an Existing Telestroke Infrastructure to Battle a Pandemic -

Jillian M Heisler^{1*}, Mark R Etherton², Anand Viswanathan²,
Lee Schwamm² and Rajan R Gadhia¹

¹Department of Neurology, Eddy Scurlock Stroke Center, Houston Methodist, Houston, TX, USA

²JPK Stroke Research Center, Department of Neurology, Massachusetts General Hospital (MGH) and
Harvard Medical School, Boston, MA, USA

Table 1: Time to thrombolytic therapy at HMH in 2020

Door to Needle (DTN)

Month	Avg (Min.)	Median (Min.)	# of Patients
January	50.9	45.0	n = 14
February	42.3	43.5	n = 14
March*	63.0	67.5	n = 8
April**	57.6	45.0	n = 7

*First suspected cases of COVID in Houston, TX USA

**Implementation of a telestroke-based evaluation for all suspected acute strokes.

55% DTN increase with COVID (Median – Feb to Mar Month over Month)

33% DTN decrease with implementation of Tele-neurology (Median – Mar to Apr Month over Month)

- 58-year-old woman (Jane Doe) brought to ED after being found altered and unsteady in a parking lot.
- ED triage team evaluates patient, and immediately suspects an acute neurological emergency, and acute TeleStroke team is activated as patient is transported to the CT scanner.


Acute Evaluation



perfectserve



Epic



Beyond Clinical Care – Research



Music Therapy in Stroke Care


Maegan Morrow, Senior Music Therapist

October 20, 2022

Center for Performing Arts Medicine Mission

to effectively translate the collaborative potential of arts and medicine to the holistic healthcare environment of Houston Methodist

- Specialized health care and education for performing artists,
- Effective and meaningful integration of the performing and visual arts into the hospital environment,
- Creative Arts Therapy that utilizes the arts in support of patient goals, and
- Research that harnesses the broadest potential of the arts in therapy, rehabilitation and human performance.



HMH (music and art therapy)

- Acute Psychiatry
- Outpatient Behavioral Health
- Inpatient Rehabilitation
- Outpatient Oncology
- BMT
- CVICU
- SLICU
- Palliative Care

HMB (music therapy)

- ICU (open position)

HMSL (music therapy)

- Cancer Infusion Center

HMWB (music therapy)

- Neonatal ICU

HMW

- ICU (open position)

HMTW (music therapy)

- Comprehensive Stroke Team

Music Therapy Credential

Music Therapy Degree
(Undergrad/Equivalency/Graduate from AMTA approved program)

1200 Clinical Fieldwork Hours
(from approved AMTA site)

Board Certification Exam

MT-BC Credential



What is Music Therapy?

- Music therapy is the clinical & evidence-based use of music interventions to accomplish individualized goals within a therapeutic relationship by a credentialed professional who has completed an accredited music therapy program.
(AMTA)

Not about teaching/developing musical skills

Concept of change

Social and humanistic psychological roots

Functional change

- Communication, cognition, physical, social, emotional and neurological functioning

All ages, groups, individuals

Goals:

- Reduce anxiety/depression associated with medical trauma
- Promote reality orientation during ICU delirium
- Promote emotional processing of medical trauma
- Enhance respiratory strengthening in preparation for vent weaning
- Promote opportunities for family bonding through end-of-life legacy work

Interventions: songwriting, salient live music for orientation/grounding, music-assisted guided imagery, OMREX (oral motor and respiratory strengthening exercises) with harmonica, rhythmic diaphragmatic breathing, and heartbeat recordings.

- Is there a biological basis for the experiences that people talk about?
 - Heart rate increases, breathing deepens, their muscle tension increases
 - Human body falls into synchronism with a rhythmic phenomenon
 - Hormones and neurochemicals
 - Adrenaline, cortisol and ACTH
 - Prolactin, oxytocin, dopamine

- Specific parts of the brain are involved in perceiving different musical elements
 - Pitch, harmony, melody, dynamics, rhythm
 - e.g., specific neurons in the auditory cortex are tuned to perceive specific pitches
- Some of the areas involved: auditory cortex, motor cortex, prefrontal cortex, sensory cortex, the visual cortex, nucleus accumbens, and amygdala, hippocampus and so on



- Hearing music
 - Auditory cortex
 - Core: pitch and volume
 - Surrounding: timbre, melody and rhythm
- Imagining Music
 - Auditory cortex to a lesser magnitude
 - Inferior frontal gyrus (retrieving memory)
 - Dorsolateral frontal cortex (working memory)



- Playing music
 - Auditory cortex (feedback system)
 - Visual cortex (reading a score)
 - Parietal lobe (e.g., computation of finger position)
 - Motor cortex
 - Sensory cortex
 - Frontal lobe
 - Cerebellum

Music as a Reward

- Emotional reaction to music
 - Reward structures such as ventral tegmental area (when you get chills!)
 - Same areas that get activated while
 - Eating
 - Sex
 - Using drugs
 - Pleasing song → inhibition of amygdala



Paradigm Shift

From MT to NMT


- Traditionally, music in therapy has been based on a model that uses music to facilitate concepts of well-being.
- Neuroscience research with the help of neuro-imaging has shifted the model to a perceptual model.
- They are based on how music perception and production engage the brain in ways translated to non-musical therapeutic learning and training.

- The essence of recovery

The brain's ability to reorganize itself by forming new neural connections throughout life.

Neuroplasticity allows the neurons (nerve cells) in the brain to compensate for injury and disease and to adjust their activities in response to new situations or to changes in their environment.

Auditory Cortex



Entrainment



Researchers demonstrated a relationship between neural processing of auditory stimuli and the arousal of the motor system, resulting in an entrainment effect.




is the therapeutic application of music to **cognitive, sensory** and **motor** dysfunction due to neurologic disease of the human nervous system.



is based on a neuroscience model of music **perception** and **production**, and the influence of music on functional changes in the non-musical brain.

Shared Rehabilitation Goals



Rhythm and the Brain



RHYTHM IS PROCESSED
SUBCORTICALLY



THE BRAIN PROCESSES
THE SPACE *BETWEEN* THE
BEATS



RHYTHM ASSISTS IN
ANTICIPATION OF
MOVEMENT AND FLUENCY
OF MOVEMENT



RHYTHM ACTS AS A
PRIMING MECHANISM TO
THE MOTOR SYSTEM

- Sensorimotor Training



Rhythmic Auditory
Stimulation



Patterned Sensory
Enhancement



Therapeutic Instrumental
Music Performance

- Melodic Intonation Therapy (MIT)
- Musical Speech Stimulation (MUSTIM)
- Rhythmic Speech Cuing (RSC)
- Vocal Intonation Therapy (VIT)
- Oral Motor and Respiratory Exercises (OMREX)
- Developmental Speech and Language Training through Music (DSLTM)
- Therapeutic Singing (TS)
- Symbolic Communication through Music (SYCOM)

- Musical Sensory Orientation Training (MSOT)
- Musical Neglect Training (MNT)
- Auditory Perception Training (APT) – 2 subcategories
- Musical Attention Control Training (MACT) – 4 subcategories
- Musical Executive Function Training (MEFT)
- Musical Mnemonics Training (MMT)
- Associative Mood and Memory Training (AMMT)
- Music Psychotherapy and Counseling (MPC)

- Rhythm has physiological function to stimulate movement

Applies auditory sounds to movement (walking, stepping)
2/2, 2/4

Therapist gradually increases to form a pattern

Rhythmic entrainment, priming of auditory motor pathway, cueing of movement

Rhythmic Auditory Stimulation



Music Therapy in Rehabilitation

Goal: Increase endurance during ambulation

Intervention: Rhythmic Auditory Stimulation (RAS)

RAS has been included in
the official Canadian Stroke
Best Practice Guidelines

Clinical Practice Guidelines
for the Management of
Stroke Rehabilitation of the
U.S. Veterans Administration
and the Department of
Defense

Therapeutic Instrumental Performance



Utilizes musical instruments to help patients to exercise impaired motor function and regain functional patterns of movement

- Utilizes a patient's unimpaired ability to sing to facilitate speech production
- Focuses on functional sentences and brief statements that are translated in melody
- Melody is developed based on inflection patterns
- Later stages of treatment the singing is reduced to “speech singing” and finally retranslated to normal speech prosody


- Addressing the improvement of articulatory control, respiratory strength, and function of the speech apparatus
- Using instruments such as:
 - Harmonica
 - Kazoo
 - Recorder

- Promotes improved walking (gait) patterns
- Improves affected limb functions (arms, hands, etc.)
- Helps improve speech (aphasia, apraxia, dysarthria)
- Improves cognitive functioning (attention, memory)
- Alleviates post-stroke anxiety and depression
- Promotes “massed practice” for neuroplasticity

19 Current Procedural Terminology (CPT) codes that may be used for music therapy services.



Medicare, Medicaid, Private Insurance, and Third-Party Payer.



Most reimbursed services support children on the autism spectrum and those with developmental delays.



Does not always impede clients from benefiting from other therapeutic services.

The Harrison Center for Music Therapy

www.harrisoncentermt.com

Houston Aphasia Recovery Center HARC

www.harctx.org

Questions or Resources



mmmorrow@houstonmethodist.org



www.musictherapy.org

My Brain on Foo Fighters



Further Reading

- Moore, Emma et al. “Diffusion tensor MRI tractography reveals increased fractional anisotropy (FA) in arcuate fasciculus following music-cued motor training.” *Brain and Cognition*. Vol. 116, August, 2017.
- Peretz, Isabelle and Robert J. Zatorre, “Brain Organization for Music Processing,” *Annual Review of Psychology*, vol. 56, 2005.
- Sacks, Oliver, *Musicophilia: Tales of Music and the Brain*, 2007.
- Schlaug, Gottfried et al., “Music Listening and Music Making in the Treatment of Neurological Disorders and Impairments,” *Music Perception*, vol. 27, no. 4, 2010.
- Thaut, Michael H., “Entrainment and the Motor System,” *Music Therapy Perspectives*, vol. 31, 2013.
- Thaut, Michael H., “Neurologic Music Therapy in Cognitive Rehabilitation,” *Music Perception*, vol. 27, no. 4, 2010.
- Thaut, Michael H. et al., “Neurobiological foundations of neurologic music therapy: rhythmic entrainment and the motor system.” *Frontiers in Psychology*. Vol. 5, February 18, 2015.
- Thaut, Michael H. and Gerald C. McIntosh, “How Music Helps to Heal the Injured Brain: Therapeutic use Crescendos Thanks to Advances in Brain Science,” *Cerebrum*, March 2010.
- Thaut, Michael H. and Mutsumi Abiru, “Rhythmic Auditory Stimulation in Rehabilitation of Movement Disorders: A Review of Current Research,” *Music Perception*, vol. 27, no. 4, 2010.

Houston Methodist Update

Marc L. Boom, MD
President and CEO

October 20, 2022



COVID-19 Viral Load Detected in City of Houston Wastewater

HOUSTON

October 10, 2022

Viral Load:



39%

In comparison to July 6, 2020

Positivity Rate:


7%

COVID-19 Viral Load in Wastewater
(Compared to July 6, 2020)




Houston Methodist COVID-19 Cases By Day

Houston Methodist COVID-19 Patients by Day




Data as of October 16, 2022



IF CASES ARE DOWN IN MY COMMUNITY,
WHY SHOULD I GET THE NEW BOOSTER?

THE VIRUS THAT CAUSES COVID-19
CHANGES OVER TIME. KEEP YOUR
PROTECTION AGAINST COVID-19 UP TO
DATE BY GETTING A BIVALENT COVID-19
VACCINE BOOSTER DOSE.

HOW DO THE UPDATED VACCINES
DIFFER FROM THE ORIGINAL ONE?



THE UPDATED (BIVALENT) BOOSTERS ARE CALLED “BIVALENT” BECAUSE THEY PROTECT AGAINST BOTH THE ORIGINAL VIRUS THAT CAUSES COVID-19 AND THE OMICRON VARIANT BA.4 AND BA.5.

HOW EFFECTIVE IS THE NEW
BOOSTER AGAINST OMICRON?

RESEARCH SUMMARY

A Bivalent Omicron-Containing Booster Vaccine against Covid-19

Chalkias S et al. DOI: 10.1056/NEJMoa2208343

CLINICAL PROBLEM

Covid-19 vaccines have had decreasing effectiveness against the omicron variant, with many breakthrough infections reported. Having the ability to boost immune response in the face of omicron is important.

CLINICAL TRIAL

Design: An ongoing, open-label, phase 2-3 trial examined the safety and immunogenicity of an omicron-specific booster vaccine in persons who were fully vaccinated against Covid-19.

Intervention: 819 participants who had received a two-dose primary series of the mRNA-1273 vaccine plus a booster dose at least 3 months earlier were given a second booster with either the bivalent mRNA-1273.214 vaccine (containing 25 µg each of ancestral Wuhan-Hu-1 and omicron B.1.1.529 spike mRNAs) or the monovalent 50-µg mRNA-1273 booster (containing Wuhan-Hu-1). The primary objectives were to assess the safety, reactogenicity, and immunogenicity of mRNA-1273.214 at 28 days, as shown by noninferior or superior neutralizing antibody responses against omicron and noninferior responses against ancestral SARS-CoV-2 with the D614G mutation.

RESULTS



Immunogenicity: In participants without previous SARS-CoV-2 infection, the bivalent booster prompted a superior neutralizing antibody response to omicron and was noninferior to the monovalent booster in generating neutralizing antibodies against ancestral SARS-CoV-2 (D614G). Higher neutralizing antibody responses against both omicron and ancestral SARS-CoV-2 were also observed in participants with previous SARS-CoV-2 infection who were given the bivalent booster.

Safety and Reactogenicity: Safety and reactogenicity were similar in the two groups.

LIMITATIONS

- The trial was not randomized.
- Variant sequences were not ascertained among those infected with Covid-19.
- Follow-up was short, so it is not known how long antibodies persist.
- The trial was not designed to evaluate vaccine effectiveness.


Links: Full Article | NEJM Quick Take




CONCLUSIONS

Among vaccinated persons who had received a booster against Covid-19, the bivalent omicron-containing mRNA-1273.214 vaccine had a safety and reactogenicity profile similar to that of the monovalent mRNA-1273 booster vaccine and was superior in eliciting a neutralizing antibody response against the omicron variant.

A Neutralizing Antibody Titers against Ancestral SARS-CoV-2 (D614G)



B Neutralizing Antibody Titers against Omicron Variant



WHO IS ELIGIBLE FOR THE OMICRON BOOSTER
RIGHT NOW?

HOW LONG SHOULD I WAIT IF I RECENTLY
RECEIVED A BOOSTER DOSE?

DO I NEED TO GET AN UPDATED BOOSTER IF
I JUST HAD COVID-19?



COVID-19 VACCINE BOOSTER UPDATE

Everyone 5 years and older should get an updated booster

- If they have completed their primary series
- If it has been at least 2 months since their final primary dose or last booster



cdc.gov/coronavirus



Vaccination history	➡	Next dose
Primary series	At least 2 months ➡	1 bivalent booster dose
Primary series + 1 booster	At least 2 months ➡	1 bivalent booster dose
Primary series + 2 booster	At least 2 months ➡	1 bivalent booster dose

WHAT ABOUT MYOCARDITIS?

GET THE FACTS

COVID-19, Myocarditis, and Vaccines



Myocarditis is inflammation of the heart muscle. This can happen after viral infections like COVID-19 and, very rarely, after receiving mRNA COVID-19 vaccines.

Most people with myocarditis following vaccination recover completely with rest and simple treatment. However, myocarditis from COVID-19 can be very severe.

If you're **UNVACCINATED**:



4X to 8X
higher risk
of myocarditis from
COVID-19 infection
in all ages.



10x
higher risk
of hospitalization
from COVID-19
infection.

If you received the COVID-19 vaccine:



The overall risk of
myocarditis is
EXTREMELY LOW.

1 IN 200,000




Young males (12-29 yrs)
have a slightly higher
risk, but still **VERY LOW.**

1 IN 14,000



Young females
(12-29 yrs) have a
MUCH LOWER risk.

LESS THAN 1 IN 100,000



For more information on vaccines, visit:
COVID19LearningNetwork.org

COVID-19 Real-Time Learning Network

Brought to you by CDC and **HHS**



© 2022, Infectious Diseases Society of America. Reprinted with permission.

This resource was created in part by a cooperative agreement with the Centers for Disease Control and Prevention (grant number R01CE000074). The Centers for Disease Control and Prevention is an agency within the Department of Health and Human Services (HHS). The contents of this resource do not necessarily represent the policy of CDC or HHS, and should not be construed as endorsement by the Federal Government.

NEW COVID-19 BOOSTERS FAQ

Q: Did the FDA and CDC approve this new booster?

A: Yes. They applied for EUA and were approved. [Click here](#) to see the fact sheet on the Pfizer bivalent vaccine booster, and [click here](#) to see the fact sheet on the Moderna bivalent vaccine booster.

Q: How do the new COVID-19 vaccine boosters differ from the existing vaccines and boosters?

A: These vaccines were specifically formulated to target the new COVID-19 variants. They are called bivalent because half of the COVID-19 vaccine booster targets the original COVID-19 virus, and the other half works against the Omicron variant, including the spike protein for BA.4 and BA.5 subvariants, which now account for nearly 100% of our positive COVID-19 cases.

Q: How do these new COVID-19 vaccine boosters work?

A: According to Pfizer, the bivalent vaccine contains mRNA encoding the original SARS-CoV-2 spike protein, which is present in the original COVID-19 vaccines, together with mRNA encoding the spike protein of the Omicron BA.4/BA.5 variants.

The booster stimulates the body's immune system and works by causing the body to produce antibodies against the virus that causes COVID-19. Similar to the original COVID-19 vaccines, this vaccine uses mRNA that carries instructions that cells in the body can use to make the spike protein, and the cells then make antibodies against the spike protein to help fight off the virus.

Q: Who is eligible for the new bivalent COVID-19 vaccine boosters?

A: The FDA granted EUA for the use of the Pfizer COVID-19 bivalent vaccine booster for individuals 12 years and older, while the Moderna COVID-19 bivalent vaccine booster received EUA for individuals 18 and older. The bivalent COVID-19 vaccine boosters are authorized as a single dose in people who have completed a primary vaccination series.

People who have already received the initial two-shot series of either vaccine are eligible, as well as those who have received the original vaccine plus one or two booster shots.

Q: How long should I wait if I just received the existing COVID-19 vaccine booster?

A: According to the FDA, you should wait at least two months following the primary vaccine series or booster vaccination.

Q: Does immunity still take two weeks to develop after this shot?

A: Antibody titers will start to rise within days after getting the shot, but it will probably take a couple of weeks to get the highest amount of antibodies, according to experts at Johns Hopkins School of Health.

Q: How long should I wait to get the bivalent booster if I just had COVID-19?

A: The FDA and CDC authorized the bivalent vaccine boosters for two months after previous boosters or infection. Some experts say it may be beneficial to wait a little longer.



Q: Can I still get the original vaccine boosters?

A: No, the COVID-19 vaccine boosters that target only the original strain are no longer authorized as boosters in people 12 years old and older.

Q: How do I know these new COVID-19 vaccine boosters are safe since they were only tested on mice?

A: FDA officials say the public can rest assured that a great deal of care has been taken to ensure that these bivalent COVID-19 vaccine boosters meet the agency's rigorous safety, effectiveness and manufacturing quality standards for EUA.

According to the FDA, for each bivalent COVID-19 vaccine, the FDA based its decision on the totality of available evidence, including extensive safety and effectiveness data for each of the original COVID-19 vaccines in humans, safety and immunogenicity data obtained from a clinical study of a bivalent COVID-19 vaccine that contained mRNA specifically targeted to fight the omicron variant BA.1 variant in humans that is similar to each of the vaccines being authorized, and nonclinical data obtained using a bivalent COVID-19 vaccine that contained mRNA of the original strain and mRNA in common between the BA.4 and BA.5 lineages of the omicron variant. Human clinical trials of the bivalent vaccines targeting BA.4 / BA.5 are ongoing.

Based on the data supporting each of these authorizations, the bivalent COVID-19 vaccines are expected to provide increased protection against the currently circulating omicron variant. Individuals who receive a bivalent COVID-19 vaccine may experience side effects commonly reported by individuals who receive authorized or approved monovalent mRNA COVID-19 vaccines, according to the FDA.

FDA officials explained in a press conference that they have extensive experience with strain changes for annual influenza vaccines, which also do not require clinical trials. They are very confident that they will increase immunization to the new variants and reduce the risk of serious outcomes and hospitalizations.

Q: Why haven't these vaccine boosters been tested on humans?

A: The FDA studied mice trial data — and human clinical trial results from a similar vaccine that targets the original omicron strain (BA.1) and extensive research on mRNA technology — to evaluate the new shots in an effort to get them out as soon as possible, according to [recent tweets](#) from the FDA commissioner, Dr. Robert Califf. Both companies are currently conducting human clinical trials on the new bivalent vaccine boosters targeting BA.4/BA.5.

Q: If I got the Pfizer COVID-19 vaccine and booster, do I need the Pfizer bivalent shot or can I get Moderna?

A: No, according to the FDA, the updated booster you receive does not need to be from the same manufacturer that made the vaccine you received for your primary vaccination or previous booster.

Q: Why should I get the bivalent COVID-19 vaccine booster?

A: The BA.5 strain accounts for the vast majority of new COVID-19 cases in the U.S., according to the [Centers for Disease Control and Prevention](#). These new vaccines are designed to significantly increase your immunity to the highly contagious virus and prevent severe disease.

Experts are predicting another wave of COVID-19 in the fall and winter, and the bivalent vaccine boosters will help protect you against serious outcomes in the future. FDA officials also say staying up to date on COVID-19 vaccines and boosters will also help prevent long COVID symptoms if you contract COVID-19 in the future.

INTO *the* WILD

With Houston Methodist

MONDAY, NOVEMBER 7, 2022 | 6-8:30 P.M.

MASIHARA PAVILION *at the* HOUSTON ZOO

6200 Hermann Park Drive | Houston, TX 77030

HOUSTON
Methodist
LEADING MEDICINE



THANK YOU FOR ATTENDING OUR TOWN HALL CONVERSATION

If you would like more information about stroke prevention and treatments,
please contact Emily Timm at **etimm@houstonmethodist.org**

If you would like more information about The Society for Leading Medicine,
please contact Amanda Harris at **abharris@houstonmethodist.org**

Take care and be well

